文献速递核素与放射性配体治疗

超越相似性:[¹⁷⁷Lu]Lu-DOTATOC治疗神经内分泌肿瘤的总生存与预后分析

Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-28

该单中心回顾性分析纳入141例接受[¹⁷⁷Lu]Lu-DOTATOC肽受体放射性核素治疗(PRRT)的神经内分泌肿瘤(NET)患者,全因死亡85例(60.3%),中位总生存期(OS)为55.2个月。多因素Cox回归显示基线De Ritis比值、碱性磷酸酶(ALP)、嗜铬粒蛋白A(CgA)及既往mTOR抑制剂治疗是OS的显著预后因素,总体缓解率为12%,疾病控制率为72%。

要点

  • 141例NET患者接受[¹⁷⁷Lu]Lu-DOTATOC PRRT,中位OS为55.2个月,全因死亡85例(60.3%)。
  • 多因素分析示基线De Ritis比值、ALP、CgA及既往mTOR抑制剂治疗与OS显著相关。
  • 总体缓解率12%,疾病控制率72%;原发肿瘤部位和CgA与原发进展风险显著相关。

核心结论

  • 常规临床实践中的OS分析显示,[¹⁷⁷Lu]Lu-DOTATOC PRRT是NET患者的有效治疗选择,且产生的[¹⁷⁷mLu]极少。
  • 所评估的预后因素可能有助于识别尤其受益于缩短随访间隔的患者。

研究设计与样本

  • 单中心回顾性分析,纳入141例接受[¹⁷⁷Lu]Lu-DOTATOC PRRT的NET患者。
  • 肿瘤分级:G1占21%,G2占71%,G3占4%,分级未知占4%。
  • 原发部位:小肠NET占48%,胰腺NET占27%,结直肠占9%,胃占1%,肺占7%,原发灶不明NET占9%。
  • 采用Cox回归和逻辑回归分析OS或原发进展风险的预后因素。

主要发现

  • 141例中全因死亡85例(60.3%)。
  • 中位OS为55.2个月;小肠NET G1-G2为62.7个月,胰腺NET G1-G2为41.2个月,NET G3为26.3个月。
  • 多因素Cox回归显示基线De Ritis比值(p < 0.001)、ALP(p < 0.001)、CgA(p < 0.001)及既往mTOR抑制剂治疗(p = 0.005)是OS的显著预后因素。
  • 总体缓解率为12%,疾病控制率为72%。
  • 多因素逻辑回归显示原发肿瘤部位(p = 0.04)和CgA(p = 0.01)是原发进展风险较高的显著预后因素。

临床怎么用

  • 原文结论认为[¹⁷⁷Lu]Lu-DOTATOC PRRT是NET患者的有效治疗选择,且产生的[¹⁷⁷mLu]极少。
  • 原文指出所评估的预后因素可能有助于识别尤其受益于缩短随访间隔的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapy with [177Lu]Lu-DOTATATE is well established for neuroendocrine tumors (NET), but its production generates [177mLu], raising concerns about waste disposal due to its longer half-life. In contrast, [177mLu] is not formed during [177Lu]Lu-DOTATOC production. However, data on overall survival (OS) and prognostic factors for [177Lu]Lu-DOTATOC remain limited, and its efficacy compared to [177Lu]Lu-DOTATATE is uncertain. This study aimed to analyze OS and radiological response in NET patients treated with [177Lu]Lu-DOTATOC. METHODS: Monocentric, retrospective analysis of 141 patients with NET (grading: 21% G1, 71% G2, 4% G3, 4% grading unknown; primary: 48% small intestine (SI-NET); 27% pancreas (P-NET); 9% colon/rectum; 1% stomach, 7% lung; 9% CUP-NET) receiving PRRT with [177Lu]Lu-DOTATOC. Cox and logistic regression were used to identify prognostic factors for OS or risk of primary progression. RESULTS: Death from any cause was observed in 85 of 141 patients (60.3%). Median OS was 55.2 months (SI NET G1-G2: 62.7 months; P-NET G1-G2: 41.2 months; NET G3: 26.3 months). Multivariable Cox regression identified baseline De Ritis Ratio (p < 0.001), ALP (p < 0.001), CgA (p < 0.001) and prior therapy with mTOR-inhibitors (p = 0.005) as significant prognostic factors of OS. Overall response rate was 12% and disease control rate was 72%. In multivariable logistic regression, primary tumor location (p = 0.04) and CgA (p = 0.01) were significant prognostic factors for higher risk of primary progression. CONCLUSION: The analysis of OS from routine clinical practice shows that PRRT with [177Lu]Lu-DOTATOC is an effective treatment option for NET patients, while generating minimal [177mLu]. The evaluated prognostic factors could help to identify patients who particularly benefit from shorter follow-up intervals.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ruhwedel T, Rogasch J, Schatka I, et al. Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2025. PMID: 40148509. doi:10.1007/s00259-025-07221-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。